

Claims

1. A composition comprising a placental stem cell which expresses at least one marker selected from the group consisting of: Thy-1, OCT-4, SOX2, SSEA3, SSEA4, TRA1-60, TRA1-81, Lefty A, FGF-4, Rex-1 and TDGF-1.
- 5 2. A composition comprising a placental stem cell which expresses at least two markers selected from the group consisting of: Thy-1, OCT-4, SOX2, SSEA3, SSEA4, TRA1-60, TRA1-81, Lefty A, FGF-4, Rex-1 and TDGF-1.
- 10 3. A composition of claim 1 that is ATCC deposit No. _____.
4. A pharmaceutical composition comprising an effective amount of the composition of claim 1 and a pharmaceutically acceptable carrier.
- 15 5. A method of making a cardiomyocyte comprising culturing a stem cell of claim 1 in a media that contains an appropriate amount of ascorbic acid 2-phosphate under appropriate conditions and for a sufficient period of time for the stem cell to differentiate into a cardiomyocyte.
6. A cardiomyocyte obtained from the process of claim 5, which expresses at least one marker selected from the group consisting of: MLC-2A, MLC-2V, hANP, cTnT, alpha- actinin, GATA-4 and Nkx 2.5.
- 20 7. A cardiomyocyte obtained from the process of claim 5, which expresses at least two markers selected from the group consisting of: MLC-2A, MLC-2V, hANP, cTnT, alpha- actinin, GATA-4 and Nkx 2.5.
8. A cardiomyocyte that is ATCC deposit No. _____.
9. A pharmaceutical composition comprising an effective amount of a cardiomyocyte of claim 6 and a pharmaceutically acceptable carrier.

10. A method of determining whether a test agent is toxic to a cardiomyocyte, comprising contacting the cardiomyocyte of claim 6 with an appropriate amount of the test agent for a time sufficient for a toxic effect on the cardiomyocyte to be detected, and determining whether the test agent has a toxic effect on the
5 cardiomyocyte.
11. A method of determining a metabolic product of a test agent comprising contacting the cardiomyocyte of claim 6 with an appropriate amount of the test agent for a time sufficient for the test agent to be metabolized, and detecting the presence of the metabolized product.
- 10 12. A method of making a hepatocyte comprising culturing a stem cell of claim 1 in a media that contains an appropriate amount of dexamethasone, ITS, EGF, FGF-2, FGF-4, FGF-7, HGF, phenobarbital, Type-I collagen or a combination thereof under appropriate conditions and for a sufficient period of time for the stem cell to differentiate into a hepatocyte.
- 15 13. A hepatocyte obtained from the process of claim 12, which expresses at least one marker selected from the group consisting of: albumin, CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4, AFP, A1AT, HNF1, HNF4 and C/EBP alpha.
- 20 14. A hepatocyte obtained from the process of claim 12, which expresses at least two markers selected from the group consisting of: albumin, CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4, AFP, A1AT, HNF1, HNF4 and C/EBP alpha.
15. A hepatocyte that is ATCC deposit No. _____.
- 25 16. A pharmaceutical composition comprising an effective amount of a hepatocyte of claim 13 and a pharmaceutically acceptable carrier.

17. A method of determining whether a test agent is toxic to a hepatocyte comprising
contacting the hepatocyte of claim 13 with an appropriate amount of the test agent
for a time sufficient for a toxic effect on the hepatocyte to be detected, and
determining whether the test agent has a toxic effect on the hepatocyte.
- 5 18. A method of determining a metabolic product of a test agent comprising
contacting the hepatocyte of claim 13 with an appropriate amount of the test agent
for a time sufficient for the test agent to be metabolized, and detecting the
presence of the metabolized product.
- 10 19. A method of making a pancreatic cell comprising culturing a stem cell of claim 1
in a media that contains an appropriate amount of nicotinamide, dexamethasone,
ITS, matrigel or a combination thereof under appropriate conditions and for a
sufficient period of time for the stem cell to differentiate into a pancreatic cell.
- 15 20. A pancreatic cell obtained from the process of claim 19, which expresses at least
one marker selected from the group consisting of: Pax6, Pdx1, insulin, glucagon,
and Nkx2.2.
21. A pancreatic cell obtained from the process of claim 19, which expresses at least
two markers selected from the group consisting of: Pax6, Pdx1, insulin,
glucagon, and Nkx2.2.
22. A pancreatic cell that is ATCC deposit No. _____.
- 20 23. A pharmaceutical composition comprising an effective amount of a pancreatic
cell of claim 20 and a pharmaceutically acceptable carrier.
24. A method of determining whether a test agent is toxic to a pancreatic cell
comprising contacting the pancreatic cell of claim 20 with an appropriate amount
of the test agent for a time sufficient for a toxic effect on the pancreatic cell to be

detected, and determining whether the test agent has a toxic effect on the pancreatic cell.

25. A method of determining a metabolic product of a test agent comprising contacting the pancreatic cell of claim 20 with an appropriate amount of the test agent for a time sufficient for the test agent to be metabolized, and detecting the presence of the metabolized product.
- 5
- 10
26. A method of making a neural cell comprising culturing a stem cell of claim 1 in a media that contains an appropriate amount of trans-retinoic acid or FGF-4 under appropriate conditions and for a sufficient period of time for the stem cell to differentiate into a neural cell.
27. A neural cell obtained from the process of claim 26, which expresses at least one marker selected from the group consisting of: GFAP, CNP, beta-tubulin III, Nestin, GAD, NSE, NF-M and MBP.
28. A neural cell obtained from the process of claim 26, which expresses at least two markers selected from the group consisting of: GFAP, CNP, beta-tubulin III, Nestin, GAD, NSE, NF-M and MBP.
- 15
29. A neural cell that is ATCC deposit No. _____.
30. A pharmaceutical composition comprising an effective amount of a neural cell of claim 27 and a pharmaceutically acceptable carrier.
- 20
31. A method of determining whether a test agent is toxic to a neural cell comprising contacting the neural cell of claim 27 with an appropriate amount of the test agent for a time sufficient for a toxic effect on the neural cell to be detected, and determining whether the test agent has a toxic effect on the neural cell.
32. A method of determining a metabolic product of a test agent comprising contacting the neural cell of claim 27 with an appropriate amount of the test agent
- 25

for a time sufficient for the test agent to be metabolized, and detecting the presence of the metabolized product.

- 5 33. A method of making a vascular endothelial cell comprising culturing a stem cell of claim 1 in a media that contains matrigel under appropriate conditions and for a sufficient period of time for the stem cell to differentiate into a vascular endothelial cell.
- 10 34. A vascular endothelial cell obtained from the process of claim 33, which expresses the FLT-1 marker.
- 15 35. A vascular endothelial cell obtained from the process of claim 33, which has physical characteristics of cells shown in Figure 10.
- 20 36. A vascular endothelial cell that is ATCC deposit No. _____.
37. A pharmaceutical composition comprising an effective amount of a vascular endothelial cell of claim 34 and a pharmaceutically acceptable carrier.
38. A method of determining whether a test agent is toxic to a vascular endothelial cell comprising contacting the vascular endothelial cell of claim 34 with an appropriate amount of the test agent for a time sufficient for a toxic effect on the vascular endothelial cell to be detected, and determining whether the test agent has a toxic effect on the vascular endothelial cell.
39. A method of determining a metabolic product of a test agent comprising contacting the vascular endothelial cell of claim 34 with an appropriate amount of the test agent for a time sufficient for the test agent to be metabolized, and detecting the presence of the metabolized product.